Skip to content

Repligen RGEN Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
-$117.98M-3,595%
STERIS logo
STERISSTE
-$300K+88.9%
International Flavors & Fragrances logo
International Flavors & FragrancesIFF
-$7M
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfBusiness.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's gain/loss on asset sales?
Repligen (RGEN) reported gain/loss on asset sales of -$13.76M in Q1 2026.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.